新型药物是否已准备好在套细胞淋巴瘤的一线治疗中接过大旗？
Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
机构信息
Weill Cornell Medicine, New York, New York.
出版信息
Clin Adv Hematol Oncol. 2021 Jun;19(6):376-382.
Although chemotherapy has been a mainstay of the frontline treatment of mantle cell lymphoma (MCL) for many years, novel agents-including Bruton kinase inhibitors, immunomodulatory agents, and BCL2 inhibitors-have shown promise in patients with relapsed and refractory disease, and they are also being studied in the frontline setting. This review summarizes the current clinical data for using these novel agents in untreated MCL, both in combination with chemotherapy and singly, and discusses some of the trials currently under way to assess their future potential.
尽管化疗多年来一直是套细胞淋巴瘤（MCL）一线治疗的基础，但新型药物——包括布鲁顿酪氨酸激酶抑制剂、免疫调节剂和 BCL2 抑制剂——在复发和难治性疾病患者中显示出前景，并且也正在一线治疗环境中进行研究。本文综述了这些新型药物在未经治疗的 MCL 中的临床数据，包括与化疗联合应用和单独应用，并讨论了一些正在进行的评估其未来潜力的试验。
Zotero 插件